reports
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2...
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenes...
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Oper...
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024Fourth quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 34% to $4.9 billion versus fourth quarter 2024; full year 2025 Dupixent global net sales increased 26% to $17.8 billion versus 2024Fourth quarter 2025 EYLEA HD® U.S. net sales increased 66% to $506 million and total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.1 billion; fu...
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in ...
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation TARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (the Society) and today announced the top 40 finalists in the 2026, America’s oldest and most prestigious science and math competition for high school seniors. Key Takeaways: The Regeneron Science Talent Search 2026 finalists represent 35 schools across 15 states. They are co...
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Op...
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live vi...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Year...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized Phase 3 trial, and inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation TARRYTOWN, N.Y. and PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharma...
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Health...
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at . A replay and transcript of the webcast will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASD...
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Mye...
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation;...
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Inv...
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines and clinical develop...
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the E...
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflamm...
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatme...
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has...
Libtayo® (cemiplimab) Approved in the European Union as First and Only...
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of recurrence or death by 68% (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p
Regeneron Highlights Progress at American Society of Hematology (ASH),...
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy, without rituximab, as a frontline treatment for diffuse large B-cell lymphoma Other presentations span a broad range of hematolo...
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regene...
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with prospective design of these antibodies to have distinct profiles – one to provide stronger anticoagulation and the other to have a lower risk of bleeding – potentially allowing physicians to tailor a...
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endp...
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years and older compared to placebo Dupixent sBLA accepted for priority review by the U.S. FDA with a target action date of February 28, 2026 If approved, Dupixent would be the first and only medicine indicated s...
- Dave Nicoski
- Ross LaDuke
SLB.N SCHLUMBERGER NV
ZEUS OLYMPIC STEEL INC.
SEE SEALED AIR CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
OMCL OMNICELL INC.
MDXG MIMEDX GROUP INC.
LOCO EL POLLO LOCO HOLDINGS INC
HVT HAVERTY FURNITURE COS. INC.
GMED GLOBUS MEDICAL INC CLASS A
FFIC FLUSHING FINANCIAL CORP.
EXPO EXPONENT INC.
CRK COMSTOCK RESOURCES INC.
BJRI BJ'S RESTAURANTS INC.
CTS CTS CORP.
HLX HELIX ENERGY SOLUTIONS GROUP INC.
PTEN PATTERSON-UTI ENERGY INC.
NOVT NOVANTA INC
WGO WINNEBAGO INDUSTRIES INC.
WHD CACTUS INC
NRIX NURIX THERAPEUTICS
VTRS VIATRIS INC.
APA APA CORPORATION
REYN REYNOLDS CONSUMER PRODUCTS
DIBS 1STDIBS COM INC
ZI ZOOMINFO TECHNOLOGIES INC
CTO CTO REALTY GROWTH INC
JANX JANUX THERAPEUTICS INC
MCW MISTER CAR WASH INC
AFRI FORAFRIC GLOBAL PLC
FTREV FORTREA HOLDINGS INC.
INO INOVIO PHARMACEUTICALS INC.
Regeneron Announces Investor Conference Presentations
Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Jefferies London Healthcare Conference at 3:30 p.m. GMT (10:30 a.m. ET) on Monday, November 17, 20257th Annual Wolfe Research Healthcare Conference at 9:20 a.m. ET on Monday, November 17, 20258th Annual Evercore Healthcare Conference at 1:20 p.m. ET on Tuesday, December 2, 2025Citi 2025 Global Healthcare Conference at 10:30 a.m. ET on Wednesday, December 3, 2025 The sessions may be access...
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biote...
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 signaling pathway, a key driver of type 2 inflammation that contributes to multiple conditions TARRYTOWN, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Dupixent® (dupilumab) has been recognized as the “Best Biotechnology Prod...
Regeneron Reports Third Quarter 2025 Financial and Operating Results
Regeneron Reports Third Quarter 2025 Financial and Operating Results Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion GAAP EPS of $13.62 and non-GAAP EPS(a) of $11.83; third quarter 2025 includes unfavorable $0.68 impact from acquired IPR&D chargeFDA approved Libtayo® as the first and only immunotherapy for high-risk adjuvant cutaneous squamous cell carc...
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at...
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma TARRYTOWN, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society for Medical O...
DB-OTO Results in the New England Journal of Medicine Showcase Dramati...
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improvement in their hearing Among three who completed speech assessments, all showed significant improvement with one able to identify one- and two-syllable words with no visual cues and respond to distant sounds and speec...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.